Adalta Limited is an ASX-listed biotechnology company focused on the development of innovative therapies for the treatment of chronic diseases. Adalta’s core objective is to develop innovative antibody-based therapies for the prevention and treatment of chronic diseases such as inflammation, fibrosis and cancer. The company’s current operations include, a Phase 2 clinical study of its lead product, AD-114, a novel anti-PD-L1 antibody for the treatment of solid tumours, and pre-clinical programs for other novel antibodies targeting inflammatory diseases, fibrosis and cancer.